Spark Therapeutics Inc (NASDAQ:ONCE) – Research analysts at SunTrust Banks issued their Q1 2018 earnings per share (EPS) estimates for shares of Spark Therapeutics in a report released on Tuesday, according to Zacks Investment Research. SunTrust Banks analyst E. Nash forecasts that the biotechnology company will earn ($1.33) per share for the quarter. SunTrust Banks currently has a “Buy” rating and a $113.00 target price on the stock.
Spark Therapeutics (NASDAQ:ONCE) last posted its earnings results on Tuesday, November 7th. The biotechnology company reported ($1.90) EPS for the quarter, missing analysts’ consensus estimates of ($1.79) by ($0.11). The firm had revenue of $1.90 million during the quarter, compared to analysts’ expectations of $1.40 million. Spark Therapeutics had a negative return on equity of 60.01% and a negative net margin of 1,090.11%. Spark Therapeutics’s quarterly revenue was up 45.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.07) earnings per share.
A number of other equities research analysts also recently commented on the company. Raymond James Financial set a $66.00 target price on Spark Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, January 3rd. Cantor Fitzgerald set a $105.00 target price on Spark Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, January 3rd. BMO Capital Markets set a $67.00 target price on Spark Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, January 2nd. Goldman Sachs Group cut Spark Therapeutics from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $106.00 to $58.00 in a research note on Thursday, December 14th. They noted that the move was a valuation call. Finally, Barclays reissued a “buy” rating and set a $54.00 price objective on shares of Spark Therapeutics in a research note on Wednesday, December 13th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and fifteen have issued a buy rating to the company’s stock. Spark Therapeutics presently has a consensus rating of “Buy” and an average price target of $76.03.
Spark Therapeutics (NASDAQ ONCE) traded down $1.41 during trading hours on Friday, hitting $52.66. The company had a trading volume of 707,000 shares, compared to its average volume of 1,560,000. The stock has a market capitalization of $1,950.00 and a P/E ratio of -7.31. Spark Therapeutics has a 12 month low of $41.06 and a 12 month high of $91.75.
In other news, CFO Stephen W. Webster sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, November 16th. The stock was sold at an average price of $70.14, for a total transaction of $701,400.00. Following the transaction, the chief financial officer now owns 12,500 shares of the company’s stock, valued at $876,750. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Katherine A. High sold 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 31st. The shares were sold at an average price of $83.30, for a total value of $416,500.00. Following the transaction, the insider now directly owns 215,000 shares in the company, valued at approximately $17,909,500. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 62,309 shares of company stock worth $4,621,085. Insiders own 7.30% of the company’s stock.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. grew its stake in Spark Therapeutics by 15.0% in the third quarter. JPMorgan Chase & Co. now owns 1,848,988 shares of the biotechnology company’s stock worth $164,986,000 after purchasing an additional 241,016 shares in the last quarter. Ameriprise Financial Inc. grew its stake in Spark Therapeutics by 6.0% in the third quarter. Ameriprise Financial Inc. now owns 207,360 shares of the biotechnology company’s stock worth $18,489,000 after purchasing an additional 11,785 shares in the last quarter. BlackRock Inc. grew its stake in Spark Therapeutics by 11.6% in the second quarter. BlackRock Inc. now owns 2,053,734 shares of the biotechnology company’s stock worth $122,689,000 after purchasing an additional 213,520 shares in the last quarter. Amundi Pioneer Asset Management Inc. bought a new position in Spark Therapeutics in the third quarter worth approximately $5,286,000. Finally, Alyeska Investment Group L.P. bought a new position in Spark Therapeutics in the third quarter worth approximately $13,519,000. 94.91% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: “Spark Therapeutics Inc (NASDAQ:ONCE) Forecasted to Post Q1 2018 Earnings of ($1.33) Per Share” was first posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this article can be viewed at https://www.thelincolnianonline.com/2018/01/13/suntrust-banks-weighs-in-on-spark-therapeutics-incs-q1-2018-earnings-once-updated-updated.html.
Spark Therapeutics Company Profile
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.